具有SGLT2抑制活性的纳米颗粒:可能的好处和未来的未来
Habib Yaribeygi1, Mina Maleki2, Tannaz Jamialahmadi3
1Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.
Diabetes & metabolic syndrome
|October 1, 2023
概括
纳米药物递送增强了-葡萄糖携运体-2抑制剂的疗效,并减少了它们的副作用,这是一种新型抗糖尿病药物. 需要进一步的研究和临床试验才能充分实现这些纳米形式的潜力.
科学领域:
- 纳米技术在医学中的应用
- 药理学 药理学是指药理学的学科.
- 药物输送系统 药物输送系统
背景情况:
- -葡萄糖共运输体-2 (SGI-2) 抑制剂是新兴的抗糖尿病药物.
- 这些药物通过抑制脏中的葡萄糖再吸收来降低血糖.
- 与SGI-2抑制剂相关的潜在不良影响需要改进药物输送策略.
研究的目的:
- 审查SGI-2抑制剂纳米配方的最新进展.
- 探索纳米技术在提高SGI-2抑制剂的有效性和安全性方面的潜在好处.
- 要突出有关纳米-SGI-2抑制剂的研究现状.
主要方法:
- 关于纳米配方SGI-2抑制剂的最近研究的文献综述.
- 对纳米技术在抗糖尿病药物药物输送中的应用现有证据的分析.
- 综合与纳米-SGI-2抑制剂的开发和益处相关的发现.
主要成果:
- 纳米技术提供了一种有前途的方法来增强SGI-2抑制剂的治疗特性.
- 纳米配方有可能提高药物的疗效,并最大限度地减少不良影响.
- 虽然研究正在进展,但纳米-SGI-2抑制剂的临床试验仍在等待.
结论:
- 纳米药物输送系统对下一代SGI-2抑制剂显示出显著的前景.
- 进一步的研究和临床验证对于将这些纳米配方转化为临床实践至关重要.
- 纳米技术可以通过改善药物输送来优化抗糖尿病治疗.
相关概念视频
Secondary Active Transport
7.1K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.1K
Glucose Transporters
22.9K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.9K
Glucagon-like Receptor Agonists
348
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
348
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
196
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
196
Glucose Absorption Into the Small Intestine
31.8K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.8K
Dipeptidyl Peptidase 4 Inhibitors
204
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
204


